AusperBio to showcase long-term AHB-137 efficacy data at AASLD 2026
Executive summary: AusperBio will present long-term follow-up clinical data regarding its AHB-137 treatment for chronic hepatitis B through two late-breaking oral presentations at the AASLD 2026 meeting. Long-term data is critical for validating the durability and safety of hepatitis B treatments, directly influencing the path toward commercialization and regulatory approval.
Who is involved: AusperBio Therapeutics, Inc., Ausper Biopharma Co., Ltd., and the American Association for the Study of Liver Diseases (AASLD).
Likely next (inference): Detailed clinical results will be disclosed during the oral presentations at the AASLD meeting, potentially impacting investor sentiment and strategic partnerships.
AusperBio’s acceptance to deliver two late‑breaking oral presentations at the 2026 AASLD Liver Meeting signals a shift in the narrative around its investigational hepatitis B therapy, AHB‑137. Rather than focusing solely on early‑phase efficacy, the company will now share long‑term follow‑up data that address durability of response—a critical consideration for chronic HBV treatment where sustained viral suppression is needed. The selection for oral slots, as opposed to poster sessions, reflects the scientific committee’s view that the data are sufficiently mature to warrant broader discussion, indicating growing interest in oligonucleotide‑based approaches within the hepatology community. Concurrently, AusperBio’s recent $120 million Series C financing provides the capital required to move AHB‑137 toward potential commercialization and to fund additional next‑generation HBV programs. This infusion strengthens the company’s balance sheet, enabling it to advance clinical development, explore combination strategies, and potentially engage with partners or regulators earlier. In the near term, the AASLD data readout may help shape the design of pivotal trials and inform regulatory pathways, while the strengthened financial position reduces near‑term funding risk and positions AusperBio to capitalize on any positive durability signals that emerge from the conference.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base Case: Positive long-term durability shown (50%)
Validates AHB-137 development path and supports the Phase 3 registrational program.
- Data confirms sustained reduction in HBV DNA levels over the follow-up period
Upside: Superior efficacy vs current standards (20%)
Accelerates potential commercialization timelines and increases attractiveness for M&A or larger partnerships.
- Data shows significantly higher rates of functional cure or sustained suppression compared to existing therapies
Downside: Safety or durability concerns (30%)
Could delay Phase 3 trials or necessitate protocol changes to address long-term toxicity or waning efficacy.
- Emergence of new long-term adverse events or significant loss of viral suppression in late-stage follow-up
What to watch
- Oral presentation of AHB-137 long-term efficacy data at AASLD 2026
- Specific metrics on HBV DNA suppression and HBsAg loss durability
- Company updates regarding the transition to Phase 3 registrational programs
Timeline
- — AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026 (PR Newswire)
- — Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 (GlobeNewswire)
- — Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 (GlobeNewswire)
- — Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting 2026 (GlobeNewswire)
- — AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies (PR Newswire)
Analysis — what this means
Likely next events
- AASLD The Liver Meeting 2026 oral presentations
Sectors affected
- Biopharmaceuticals
- Hepatology therapeutics
Regulatory implications
- Data will be central to future FDA/EMA submissions for chronic hepatitis B treatments
Historical parallels
- Assembly Biosciences presenting Phase 1a data at AASLD 2026
Key entities
Sources
- AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026 — PR Newswire
- AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies — PR Newswire
- Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 — GlobeNewswire
- Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 — GlobeNewswire
- Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting 2026 — GlobeNewswire